Skip to main content

2004 | OriginalPaper | Buchkapitel

Appendices

verfasst von : Professor Dr. Oliver Gassmann, Gerrit Reepmeyer, Professor Dr. Maximilian von Zedtwitz

Erschienen in: Leading Pharmaceutical Innovation

Verlag: Springer Berlin Heidelberg

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Novartis was formed in 1996 through the merger of Ciba Geigy and Sandoz. Cost savings from the merger have resulted in net profit margins at the high end of the industry average; this has enabled Novartis to invest significantly in organic growth. In addition, Novartis consolidated activities with the divestment of non-core businesses. As a first and significant step, the company spun-off its CHF 8 billion specialty chemicals business Ciba SC in 1997. Afterwards, Novartis divested its CHF 5.5 billion agribusiness sector, merging it with the agrochemicals business of AstraZeneca to form Syngenta. Novartis now operates its core businesses in two divisions: pharmaceuticals and consumer health.

Metadaten
Titel
Appendices
verfasst von
Professor Dr. Oliver Gassmann
Gerrit Reepmeyer
Professor Dr. Maximilian von Zedtwitz
Copyright-Jahr
2004
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-540-24781-4_8

Premium Partner